The approval process for drug clinical trials in Japan typically takes around 12 to 18 months. This includes the time required for regulatory review by the Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour and Welfare (MHLW). Read More
The PMDA supports Japan’s drug approval processes by reviewing the drug dossier submitted, conducting scientific reviews, safety evaluations, etc. It collaborates with pharmaceutical companies to ensure compliance with regulations, accelerates approval timelines through expedited pathways, and provides guidance to enhance drug development... Read More
In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) reviews drug registration dossiers. The PMDA evaluates the safety, efficacy, and quality of new drugs before MHLW approval. Additionally, the MHLW makes the final decision based on PMDA’s assessment and recommendations. Read More
Companies can prepare for a Japan drug GMP audit by ensuring compliance with Japanese regulations, conducting internal audits, training staff, maintaining thorough documentation, and implementing robust quality management systems. Regularly reviewing and updating procedures, and engaging with local experts or consultants familiar... Read More
Reimbursement approval for medical devices in Japan typically takes around 2 to 6 months. This period includes the time required for your reimbursement submission, review by the Chuikyo, and final reimbursement approval by the Ministry of Health, Labour and Welfare (MHLW). Timelines... Read More
In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) reviews the medical device registration dossier. The PMDA evaluates the safety, efficacy, and quality of medical devices before the MHLW grants approval. Additionally, the MHLW oversees the regulatory framework and final approval process. Read More
Companies can prepare for a Japan medical device GMP audit by ensuring compliance with Japanese regulations, conducting internal audits, maintaining thorough documentation, training staff on GMP requirements, and addressing any identified gaps. Engaging with local regulatory experts and staying updated on regulatory... Read More
The approval process for medical devices in Japan typically takes around 6 to 18 months depending on the device classification. This timeframe includes the review by the Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour and Welfare (MHLW). Read More
In Japan, medical device classification is determined by the Pharmaceuticals and Medical Devices Agency (PMDA) based on risk levels. Devices are categorized into four classes (I-IV), with Class I being low-risk and Class IV high-risk. The classification considers factors like intended use,... Read More
In Japan, the MAH (Marketing Authorization Holder) or DMAH (Designated Marketing Authorization Holder) is responsible for ensuring medical devices comply with regulatory requirements, including obtaining necessary approvals, maintaining quality standards, and handling post-market surveillance. They act as the liaison between foreign manufacturers... Read More